IPSEN (EPA:IPN) | WebDisclosure

Basculer en Français

8616	Companies
142275	Keywords
78104	Articles
76024	Press releases

Home
Companies
IPSEN

PRESS RELEASE

published on 03/12/2025 at 07:28, 1 month 3 days ago

Ipsen nomme Olivia Brown au poste de Vice-Présidente Exécutive, Directrice Mondiale des Neurotoxines
Ipsen nomme Olivia Brown nouvelle VP Exécutive, Directrice Mondiale des Neurotoxines. Elle dirigera la franchise mondiale des neurotoxines et supervisera stratégie et exécution

Stratégie Ipsen Neurotoxines Olivia Brown Franchise Mondiale
PRESS RELEASE

published on 02/21/2025 at 15:42, 1 month 22 days ago

Ipsen S.A. publishes its 2024 consolidated financial statements
PRESS RELEASE

published on 02/21/2025 at 15:42, 1 month 22 days ago

Ipsen S.A. publie ses comptes consolidés 2024
PRESS RELEASE

published on 10/23/2024 at 07:00, 5 months 23 days ago

Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'année 2024 et revoit à la hausse ses prévisions pour l'exercice en cours
BRIEF

published on 09/23/2024 at 11:01, 6 months 22 days ago

Franchissement de seuil par Parvus Asset Management dans IPSEN SA

Euronext Paris Droits De Vote Franchissement De Seuil Ipsen SA Parvus Asset Management
BRIEF

published on 09/23/2024 at 11:01, 6 months 22 days ago

Parvus Asset Management crosses threshold in IPSEN SA

Euronext Paris Voting Rights Threshold Crossing Ipsen SA Parvus Asset Management
PRESS RELEASE

published on 09/23/2024 at 10:56, 6 months 22 days ago

Franchissement de seuil
Déclaration de franchissement de seuil par Parvus Asset Management Europe Limited pour le compte de clients et fonds détenant 7,80% du capital d'IPSEN SA

Droits De Vote Franchissement De Seuil Ipsen SA Parvus Asset Management Cession Actions
BRIEF

published on 09/16/2024 at 14:50, 6 months 29 days ago

Promising results for Cabometyx in advanced neuroendocrine tumors

Phase III Ipsen Neuroendocrine Tumors ESMO 2024 Cabometyx
BRIEF

published on 09/16/2024 at 14:50, 6 months 29 days ago

Des résultats prometteurs pour Cabometyx dans les tumeurs neuroendocrines avancées

Phase III Ipsen Tumeurs Neuroendocrines ESMO 2024 Cabometyx
PRESS RELEASE

published on 09/16/2024 at 14:45, 6 months 29 days ago

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
Final results from CABINET Phase III trial show significant reduction in disease progression or death risk with Cabometyx in advanced neuroendocrine tumors. Data presented at ESMO 2024 and NEJM

Phase III Trial Neuroendocrine Tumors ESMO 2024 Cabometyx Disease Progression

Accesswire

Published on 04/16/2025 at 02:25, 1 hour ago

New High-Grade Assays Extend Tolmer Silver & Gold Zones
Published on 04/15/2025 at 23:40, 3 hours 45 minutes ago

Electric Metals Announces Business Consulting Services Agreement With Terrella Capital
Published on 04/15/2025 at 23:30, 3 hours 55 minutes ago

GameSquare Holdings Reports 2024 Full Year Results
Published on 04/15/2025 at 23:30, 3 hours 55 minutes ago

AIML Announces Closing of Oversubscribed Private Placement
Published on 04/15/2025 at 23:00, 4 hours 25 minutes ago

Cerrado Gold Announces Q1 2025 Production Results At Its Minera Don Nicolas Mine In Argentina

View all ACCESSWIRE

EQS Group

Published on 04/15/2025 at 23:54, 3 hours 31 minutes ago

EQS-Adhoc: DATAGROUP enters into an Investment Agreement with and supports a public purchase offer of KKR at a price of EUR 54.00 per share in cash
Published on 04/15/2025 at 21:51, 5 hours 33 minutes ago

EQS-Adhoc: Adtran Networks SE updates preliminary results for the financial year 2024
Published on 04/15/2025 at 18:53, 8 hours 31 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/15/2025 at 18:30, 8 hours 54 minutes ago

GURIT REPORTS NET SALES OF CHF 85.2 MILLION IN THE FIRST QUARTER OF 2025; ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS
Published on 04/15/2025 at 18:00, 9 hours 25 minutes ago

ALTHEORA: RESILIENCE DES RESULTATS ANNUELS 2024

Les Echos

Published on 04/15/2025 at 19:00, 8 hours 25 minutes ago

Covivio Hotels - Descriptif du programme de rachat d’actions autorisé par l’Assemblée Générale Mixte des actionnaires du 15 avril 2025
Published on 04/15/2025 at 18:00, 9 hours 25 minutes ago

NFL Biosciences annonce la mise à disposition de son rapport financier annuel 2024
Published on 04/15/2025 at 18:00, 9 hours 25 minutes ago

Covivio Hotels - Revenus à fin mars 2025 : la croissance se poursuit
Published on 04/15/2025 at 18:00, 9 hours 25 minutes ago

Covivio Hotels - Revenues at end-March 2025: continued growth
Published on 04/15/2025 at 17:45, 9 hours 40 minutes ago

DAMARTEX / Droits de vote bruts et réels au 31 mars 2025

View all LES ECHOS COMFI WIRE